Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Group 1 - Sage Therapeutics, Inc. shares increased by 35.4% to $9.07, following a significant trading volume, contrasting with a 2.8% loss over the past four weeks [1] - Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for $8.50 per share in cash, totaling approximately $561 million, with potential additional value bringing the total to $12 per share, or about $795 million [2] - The acquisition is expected to close in Q3 2025, subject to customary conditions, with Sage projected to report a quarterly loss of $0.96 per share, a year-over-year increase of 43.5%, and revenues expected to reach $17.34 million, up 100.5% from the previous year [3] Group 2 - The consensus EPS estimate for Sage Therapeutics has been revised slightly lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [5] - Sage Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook, while another company in the same industry, Compugen, has also maintained a Zacks Rank of 3 [6][7]